Who is sponsoring NCT02310919?

NCT02310919 is sponsored by University of California, San Francisco.

What condition does NCT02310919 study?

NCT02310919 studies Infertility.

What drugs are being tested in NCT02310919?

Interventions: Low dose hCG plus FSH co-trigger, Standard dose of hCG.

What is the status of NCT02310919?

NCT02310919 is currently COMPLETED.

Last reviewed 2022-04-04 · How we verify

Concomitant Administration of FSH With a Low Dose of hCG (1,500 IU) Has Equivalent Oocyte Developmental Competence While Decreasing the Exposure to hCG in IVF Cycles: A Double Blind Randomized Control Trial

NCT02310919 Phase 3 COMPLETED Results posted

This is a randomized, double-blind, single center clinical trial study to compare oocyte competence and risk of ovarian hyperstimulation syndrome (OHSS) after receiving the standard dose of human chorionic gonadotropin (hCG) ovulation trigger or a lower dose of hCG plus concomitant follicle stimulating hormone (FSH) co-trigger in women undergoing in vitro fertilization (IVF).

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 3
Status	COMPLETED
Enrolment	105
Start date	2014-09
Completion	2018-06-20

Conditions

Infertility

Interventions

Low dose hCG plus FSH co-trigger
Standard dose of hCG

Primary outcomes

Total Fertilization Proportion (i.e. Total Competent Proportion) — 2 days
The number of fertilized oocytes (2-pronuclei) after standard in vitro fertilization or intra-cytoplasmic sperm injection divided by the total number of oocytes retrieved as a measure of oocyte competence.

Countries

United States